Premier Perspectives The blog for insider insights in clinical development Recent Posts By expertise area All expertise areas Medical DeviceRare DiseaseOncology & HematologyDiagnosticsDigital TherapeuticsMedTechPediatricsNeuroscienceAnalgesiaDermatologyOtherCOVID-19Cell & Gene TherapyWomen's HealthReal-World & Late PhaseCareers By functional area All functional areas Development StrategyClinical Research: Phase 1 - Phase 4ConsultingData Management & BiostatisticsFunctional Service Provider (FSP)Global ComplianceMedical and Regulatory AffairsPatient and Stakeholder EngagementProject ManagementQualityReal-World Science and Late PhaseSafety/PharmacovigilanceStudy DesignStudy Start-UpOtherCOVID-19Product Development Medical and Regulatory Affairs Rare Oncology and the FDA: Taking the Guesswork Out of Expedited Pathways By Premier Research June 7, 2023 Development Strategy Advancing from Research to Development: What Can Go Wrong? By Alain Guimond May 19, 2023 Clinical ResearchPhase 1 - Phase 4 In Silico Modeling Unveils a New Era in Rare Disease Drug Development By Abie Ekangaki May 4, 2023 Clinical ResearchPhase 1 - Phase 4 Beyond Boundaries: Revolutionary CAR-T Therapies Pave Way to Conquer Solid Tumors By Premier Research April 24, 2023 Clinical ResearchPhase 1 - Phase 4 To Placebo or Not to Placebo? The Great Debate in Rare Disease Trials By Jaclyn Brown March 31, 2023 Clinical ResearchPhase 1 - Phase 4 Realizing the Full Value of Patient Centricity in Rare Disease: 5 Ways to Maximize Your Engagement Efforts By Kris O'Brien March 27, 2023 Previous 1 …5 6 7 8 9 … 56 Next × ALSO OF INTERESTKey Considerations When Designing a Phase 1...Nostalgia or Shell Shock? Assessing PTSD Is a...Gene Therapy 101: From the 1960s to Today